ReviewFrontiers in genetics2025
Computational models for pan-cancer classification based on multi-omics data.
Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Beyond chromatin accessibility: bulk ATAC-seq as an integrative assay to portray genomes and epigenomes.NAR genomics and bioinformatics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor heterogeneity presents a significant challenge in cancer treatment, limiting the ability of clinicians to achieve accurate early-stage diagnoses and develop customized therapeutic strategies. Early diagnosis is crucial for effective intervention, yet current methods lack robust solutions to overcome this challenge. The Pan-Cancer Atlas has emerged as a pivotal framework to investigate cancer heterogeneity by integrating multi-omics data (genomics, transcriptomics, proteomics) across tumor types. This initiative systematically maps inter- and intratumor variations, providing insight for clinical decision making. However, such frameworks often struggle to integrate dynamic temporal changes and spatial heterogeneity within tumors, limiting their real-time clinical applicability. In this review, we first summarize the available multi-omics data and public biomedical databases used in pan-cancer research. Then, we examine current pan-cancer classification approaches based on the computational models they employed, including machine learning and deep learning. We also provide a comparison of these classification methods to explore their advantages and limitations. Finally, we conclude by discussing the key challenges in pan-cancer research and suggesting potential directions for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.